Multiple Endocrine Neoplasia Type 1

What is Multiple endocrine neoplasia type 1?

Multiple endocrine neoplasia type 1 (MEN1), also known as Wermer syndrome, is a rare hereditary disorder that causes tumors to develop in multiple hormone-producing (endocrine) glands throughout the body. This autosomal dominant genetic condition primarily affects the parathyroid glands, pancreatic islet cells, and pituitary gland, leading to overproduction of various hormones. MEN1 affects approximately 1 in 30,000 people worldwide, making it a rare but significant endocrine disorder. The condition typically manifests in adulthood, though symptoms can appear at any age, and affects men and women equally.

Key statistics

Symptoms

Common symptoms: Kidney stones, bone pain, fatigue, peptic ulcers, headaches, vision problems, muscle weakness, depression, confusion.

The symptoms of MEN1 vary widely depending on which endocrine glands are affected and which hormones are overproduced. Primary hyperparathyroidism is often the first manifestation, occurring in over 95% of patients, typically causing elevated blood calcium levels that lead to kidney stones, bone pain, fatigue, depression, and confusion. Pancreatic tumors develop in 30-80% of patients and may produce excess gastrin (causing severe peptic ulcers and diarrhea) or insulin (leading to dangerous low blood sugar episodes with sweating, confusion, and potential loss of consciousness). Pituitary adenomas occur in 15-50% of cases and can cause headaches, vision problems, and various hormonal imbalances depending on the tumor type. Some patients may experience growth hormone excess leading to acromegaly, while others develop prolactin-secreting tumors causing irregular menstrual periods in women or erectile dysfunction in men. Additional manifestations may include skin lesions, thyroid nodules, and adrenal tumors, though these are less common.

Causes and risk factors

MEN1 is caused by mutations in the MEN1 gene located on chromosome 11, which normally produces a protein called menin that helps regulate cell division and prevent tumor formation. When this gene is mutated, cells in endocrine glands can grow uncontrollably, forming tumors. The condition follows an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene from either parent is sufficient to cause the disorder. Each child of an affected parent has a 50% chance of inheriting the condition. About 90% of MEN1 cases are inherited from an affected parent, while 10% result from new (de novo) mutations. There are no known environmental risk factors that cause or worsen MEN1, as it is purely a genetic condition. Family history remains the primary risk factor, making genetic counseling crucial for affected families.

Submit Your Paper

Prevention

Since MEN1 is an inherited genetic disorder, it cannot be prevented through lifestyle modifications or environmental changes. However, early detection through genetic testing and regular screening can significantly improve outcomes by identifying tumors before they cause serious complications. Genetic counseling is essential for families with MEN1, as testing can determine whether family members carry the mutation before symptoms develop. Preimplantation genetic diagnosis (PGD) is available for couples who want to prevent passing the condition to their children. For diagnosed patients, preventive screening protocols typically begin in childhood or early adolescence for family members who test positive for MEN1 mutations. Regular monitoring allows for early intervention and better management of the condition’s manifestations.

Complications

Without proper treatment and monitoring, MEN1 can lead to serious, life-threatening complications. Severe hypercalcemia from hyperparathyroidism can cause kidney failure, cardiac arrhythmias, and neurological problems including coma. Pancreatic tumors may become malignant, with gastrinomas showing cancer potential in 60-90% of cases, though they typically grow slowly. Large pituitary tumors can compress surrounding brain structures, causing permanent vision loss or hormonal deficiencies. Zollinger-Ellison syndrome, caused by gastrin-secreting tumors, can lead to severe peptic ulcers, gastrointestinal bleeding, and perforation if untreated. Insulinomas can cause recurrent severe hypoglycemia, potentially resulting in seizures, brain damage, or death. Additionally, the psychological impact of living with multiple tumors and the uncertainty of cancer development can significantly affect mental health and quality of life.

Diagnosis

Diagnosis of MEN1 requires meeting specific clinical criteria or genetic testing. The clinical diagnosis is established when a patient has two or more of the three main MEN1-associated endocrine tumors: parathyroid, pancreatic islet cell, or pituitary adenomas. Genetic testing for MEN1 gene mutations provides definitive diagnosis and is particularly important for family screening. Laboratory tests include serum calcium and parathyroid hormone levels to detect hyperparathyroidism, gastrin levels for gastrinomas, and insulin levels during supervised fasting for insulinomas. Chromogranin A serves as a general tumor marker for pancreatic neuroendocrine tumors. Imaging studies play a crucial role, including MRI or CT scans of the abdomen to detect pancreatic tumors, MRI of the pituitary gland, and neck ultrasound or sestamibi scans for parathyroid adenomas. Endoscopic ultrasound may be needed to identify small pancreatic tumors. Genetic testing should be offered to all first-degree relatives of confirmed MEN1 patients, as early detection significantly improves outcomes.

Treatment

Treatment of MEN1 requires a multidisciplinary approach targeting each affected endocrine gland. For hyperparathyroidism, surgical removal of overactive parathyroid glands is typically necessary, often requiring subtotal parathyroidectomy or total parathyroidectomy with autotransplantation. Pancreatic tumors may require surgical resection, particularly for large or symptomatic tumors. Octreotide, a somatostatin analog, can help control symptoms from functioning pancreatic tumors. Gastrinomas are often managed with proton pump inhibitors like omeprazole or lansoprazole to reduce gastric acid production. Insulinomas typically require surgical removal due to hypoglycemia risk. For inoperable pancreatic tumors, diazoxide may help manage hypoglycemia, while everolimus, an mTOR inhibitor, has shown promise in treating advanced pancreatic neuroendocrine tumors. Pituitary adenomas may be treated surgically through transsphenoidal resection or medically with cabergoline for prolactinomas or octreotide for growth hormone-secreting tumors. Regular monitoring and follow-up are essential components of long-term management.

Prognosis

The prognosis for MEN1 patients has improved significantly with early diagnosis and comprehensive management. Life expectancy is generally reduced compared to the general population, primarily due to malignant transformation of pancreatic tumors and complications from hypercalcemia. However, with proper screening and treatment, many patients can live relatively normal lives for decades. The 10-year survival rate exceeds 80% when tumors are detected early and appropriately managed. Factors affecting prognosis include the age at diagnosis, tumor size and location, presence of metastases, and compliance with screening protocols. Pancreatic neuroendocrine tumors represent the most significant prognostic concern, as they may become malignant and metastasize. Early detection through regular screening allows for timely intervention, significantly improving outcomes and quality of life.

Quality of life

Living with MEN1 requires significant lifestyle adaptations, but many patients maintain good quality of life with proper management. Regular medical appointments and screening procedures become a central part of life, typically requiring quarterly to annual visits with endocrinologists and other specialists. Dietary modifications may be necessary, particularly avoiding calcium supplements and maintaining adequate nutrition if gastric acid suppression is required. Exercise should be encouraged to maintain bone health, especially given the risk of osteoporosis from hyperparathyroidism. Mental health support is crucial, as the chronic nature of the condition and cancer risk can cause anxiety and depression. Many patients benefit from connecting with support groups and patient advocacy organizations. Work and school accommodations may be needed during treatment periods or for managing symptoms. Open communication with family members is important, as genetic counseling and testing decisions affect multiple generations.

Pregnancy and fertility

MEN1 can significantly impact pregnancy and fertility considerations. Women with MEN1 should receive preconception counseling to optimize hormone levels and discuss medication safety. Hypercalcemia during pregnancy poses risks to both mother and fetus, potentially causing preterm labor, intrauterine growth restriction, and neonatal tetany. Pregnancy may worsen hyperparathyroidism, sometimes requiring surgical intervention during the second trimester. Prolactin-secreting pituitary tumors may expand during pregnancy due to hormonal changes, potentially causing vision problems. Genetic counseling is essential, as each pregnancy carries a 50% risk of passing MEN1 to the child. Some medications used to treat MEN1 may not be safe during pregnancy, requiring careful management by maternal-fetal medicine specialists. Preimplantation genetic testing offers an option for couples seeking to prevent transmission to their children.

Children

Children with MEN1 gene mutations typically remain asymptomatic until adolescence or early adulthood, but early screening is crucial for optimal outcomes. Pediatric screening protocols usually begin around age 8-10 years with annual biochemical testing for hyperparathyroidism. Genetic testing should be offered to children of affected parents, preferably after age 16 when they can participate in the decision-making process, though earlier testing may be considered if there are clinical concerns. Psychological support is important for children learning about their genetic status, as the knowledge of future health risks can be overwhelming. Family discussions about MEN1 should be age-appropriate and honest, emphasizing the importance of regular monitoring while maintaining hope for normal childhood activities. Pediatric endocrinologists experienced with MEN1 should oversee care, as treatment approaches may differ from adult protocols.

When to see a doctor

Immediate medical attention is required for symptoms of severe hypercalcemia, including confusion, severe fatigue, irregular heartbeat, or difficulty breathing. Signs of severe hypoglycemia from insulinomas, such as loss of consciousness, seizures, or severe confusion, constitute medical emergencies. Sudden severe headaches or vision changes may indicate pituitary tumor complications requiring urgent evaluation. Family members of MEN1 patients should seek genetic counseling and consider testing, particularly before family planning. Routine medical care should be sought for persistent symptoms like kidney stones, bone pain, peptic ulcers, or unexplained fatigue, as these may be early signs of MEN1. Anyone with a family history of multiple endocrine tumors should discuss screening with their healthcare provider, even in the absence of symptoms.

Regional context

Limited data exists regarding MEN1 prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or broader Eastern Mediterranean area. However, the condition appears to affect all ethnic populations similarly, suggesting the general prevalence of 1 in 30,000 likely applies to these regions. Genetic founder effects or population-specific mutations have been identified in some isolated communities worldwide, but comprehensive genetic studies in Caucasus populations remain limited. Access to genetic testing and specialized endocrine care may vary across the region, potentially affecting diagnosis and management. The Global Medical Journal welcomes contributions from regional healthcare providers and researchers who can provide insights into MEN1 prevalence, common presentations, and healthcare delivery challenges specific to the Caucasus and Eastern Mediterranean regions.

Research and clinical trials

Current MEN1 research focuses on improving early detection, developing targeted therapies, and understanding tumor biology. Novel treatments under investigation include targeted molecular therapies for pancreatic neuroendocrine tumors, improved imaging techniques for detecting small tumors, and gene therapy approaches. Recent breakthroughs include better understanding of the menin protein’s role in tumor suppression and identification of potential therapeutic targets. Clinical trials are exploring combination therapies, immunotherapy approaches, and new surgical techniques. Patients can search for relevant clinical trials at ClinicalTrials.gov using terms like “MEN1,” “multiple endocrine neoplasia,” or “neuroendocrine tumors.” International collaborative research efforts are working to establish standardized screening protocols and treatment guidelines. Patient registries and biobanks are collecting valuable data to accelerate research progress and improve understanding of this rare condition.

Frequently asked questions

Is MEN1 always inherited from parents?

About 90% of MEN1 cases are inherited from an affected parent, but approximately 10% result from new genetic mutations occurring for the first time in the individual. Even in these cases, the condition can still be passed to future children.

Will all my children inherit MEN1 if I have it?

Each child has a 50% chance of inheriting the MEN1 gene mutation. Genetic counseling and testing can help families understand risks and explore options like preimplantation genetic diagnosis.

Can MEN1 tumors become cancerous?

While most MEN1-associated tumors are benign, pancreatic neuroendocrine tumors have malignant potential, particularly gastrinomas. Regular monitoring allows for early detection and intervention if cancerous changes occur.

How often do I need screening if I have MEN1?

Screening frequency varies by age and symptoms but typically includes annual biochemical testing and imaging every 1-3 years. Your healthcare team will develop a personalized surveillance schedule based on your specific situation.

Can I live a normal life with MEN1?

Many people with MEN1 live full, productive lives with proper medical management. While the condition requires ongoing monitoring and treatment, early detection and modern therapies have significantly improved quality of life and outcomes.

Support and resources

International Organizations:

• Orphanet – European database of rare diseases
• National Organization for Rare Disorders (NORD) – Patient advocacy and information
• EURORDIS – European rare disease alliance
• Association for Multiple Endocrine Neoplasia Disorders (AMEND) – UK-based patient support
• Neuroendocrine Tumour Society – Support and information
• Endocrine Society – Professional medical organization with patient resources

Related conditions

Multiple endocrine neoplasia type 2, Von Hippel-Lindau disease, Neurofibromatosis type 1, Carney complex, McCune-Albright syndrome

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Cite this page

GMJ News Desk. “Multiple endocrine neoplasia type 1.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/multiple-endocrine-neoplasia-type-1/

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.